Promising clinical studies surrounding the medication Retatrutide , specifically the 120 milligram formulation ZPHC ZPHC, indicate a considerable benefit on weight reduction and related metabolic factors. Scientists anticipate that this combined agonist , targeting both GLP-1 and GIP pathways ,